The FDA Just Declared War on Cheap Ozempic

Many compounders kept going anyway. The FDA noticed.

Hims & Hers: From Poster Child to Cautionary Tale

No company rode the compounding wave harder than Hims & Hers. The telehealth giant launched compounded semaglutide in May 2024, and it immediately became a rocket booster strapped to the company's financials. That single product line generated over $225 million in revenue in 2024 and powered a 95% revenue surge in Q4 alone.

By early 2025, GLP-1 medications accounted for roughly 35-40% of the company's online revenue. Hims was on pace for about $725 million in weight-loss revenue in 2025. The stock soared to nearly $68 per share.

Then gravity kicked in.

When the FDA announced its crackdown and explicitly named Hims, the stock dropped about 14% in after-hours trading. Over subsequent weeks, shares cratered further, at one point falling below $17, which was roughly 75% off the peak. HHS referred the company to the Department of Justice for potential violations of the Food, Drug, and Cosmetic Act, a serious legal escalation that goes well beyond regulatory wrist-slapping.

Hims tried to launch a $49 compounded Wegovy pill in early 2026 and pulled it just three days later after the FDA Commissioner called such products "illegal imitations." The company ultimately struck a deal with Novo Nordisk in March 2026, agreeing to sell branded Ozempic and Wegovy on its platform and stop promoting compounded versions. The compounding gold rush was over for Hims; the company now had to sell someone else's product at someone else's margins.

Wall Street's Verdict

Analysts haven't been gentle. Cantor Fitzgerald's Prakhar Agrawal said Hims "took it one step too far" with the oral GLP-1 pill and predicted Lilly and Novo would "use all their might to litigate." Needham's Ryan McDonald called the lost oral GLP-1 opportunity a blow to Hims' "uncertain long-term growth prospects." BMO pharma analyst Evan Seigerman noted that as brand prices fall and insurance coverage improves, compounded GLP-1 volumes will naturally decline further.

Hims still projects $2.7 to $2.9 billion in total 2026 revenue, so the company isn't dying. But that implies growth of just over 15%, a far cry from the 69% growth rate it posted when compounding was booming in 2024. The high-margin engine has been replaced with a lower-margin branded distribution model. It's the difference between owning the restaurant and delivering someone else's food.

Big Pharma Gets Its Way

Novo Nordisk and Eli Lilly aren't exactly sitting on the sidelines weeping. Both companies have launched aggressive cease-and-desist campaigns against compounding pharmacies, weight-loss clinics, and med spas. Lilly has sued dozens of compounders for selling what it calls "unapproved, misbranded versions" of Mounjaro and Zepbound. Novo has pursued similar legal action while framing the effort as a patient safety initiative.

And honestly? They have a point. The FDA found real problems during those 38 inspections: drugs with the wrong potency, sterility test failures, facilities that wouldn't pass a restaurant health inspection. One compounding pharmacy's semaglutide might deliver too little active ingredient; another's might deliver too much. Neither scenario is great when you're injecting the stuff into your abdomen weekly.

But patient safety isn't the only motivation here. Novo and Lilly are protecting franchises worth tens of billions of dollars annually. Combined semaglutide and tirzepatide branded sales are projected to reach approximately $84.5 billion globally in 2026. The compounded market, estimated at a few billion dollars at its peak, was small by comparison. But it represented something dangerous to Big Pharma: proof that millions of people would choose a cheaper alternative if one existed.

What's Left Standing

Compounded GLP-1s aren't technically dead. A traditional pharmacy can still compound semaglutide or tirzepatide for a specific patient with a documented medical need, like an allergy to an excipient in the branded product. But this is the difference between a fire hose and an eyedropper. Mass production, online subscriptions, and flat-rate pricing are done.

For the hundreds of thousands of Americans who were using compounded GLP-1s because they couldn't afford branded versions — which carry list prices of $1,000-plus monthly, though manufacturer self-pay programs now offer them for $199–$499 per month — the path forward is murkier. Some will transition to branded drugs through insurance. Some will simply stop treatment. The FDA's crackdown may be legally sound and scientionally justified, but it doesn't solve the access problem that created the compounding boom in the first place.

The GLP-1 revolution continues. It's just getting a lot more expensive to participate.

The $130M Bet That CGRP Isn't the Last Word on Migraines

A new startup just raised $130 million to target the migraine pathway that CGRP drugs can't touch. Slate Medicines is betting that PACAP, a completely independent trigger system, could help the millions of patients who don't respond to current therapies.